Spotlight On... Novartis' troubled Alcon unit recalls eye drops for sterility, potency problems; Endo tanks on women's health sale; AZ sells rights to constipation drug; Denmark vies for EMA; and more...

F. Michael Ball, the former Hospira CEO who last month took over the top spot at Novartis' ($NVS) troubled Alcon unit, already had plenty on his to-do list. The division's sales are way off, it's squeezing manufacturing costs and it's dealing with a recall in Japan. Now, Ball has another recall to contend with. More from FiercePharmaManufacturing

@FiercePharma: FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Teva plots global rebrand as it prepares to join hands with Allergan's generics unit. Article | Follow @CarlyHFierce

> Endo's ($ENDP) shares tanked Monday on the news that it was selling its women's health division. Report

> The U.S. Supreme Court has declined to review a lower-court decision ordering a law firm to give $10 million in settlement proceeds from GlaxoSmithKline ($GSK) to a common benefit fund in centralized product liability suits over diabetes med Avandia. Report (sub. req.)

> A recent study published in JAMA Internal Medicine found that while Addyi, the "female Viagra" pill, does affect women's libido, it does so only modestly. Report

> AstraZeneca ($AZN) has sold European rights to opioid-induced constipation drug Moventig to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million. More

> Denmark is vying to be the new home of the European Medicines Agency (EMA) if Britons vote to leave the European Union in a June referendum. More

> French drugmaker Ipsen's full-year core operating income rose 23.8% to €322.5 million. Report

> Germany's Stada forecast a slight increase in adjusted profit this year despite its prediction that business will likely be subdued through March. Report

Medical Device News

@FierceMedDev: Walgreens plots emergency exit from partnership with Theranos: FT. More | Follow @FierceMedDev

@EmilyWFierce: UPDATED: Zepatier beats Harvoni, Sovaldi in hep C clinical-data safety showdown: Advera Health Analytics. FiercePharma story | Follow @EmilyWFierce

> German startup Retina Implant nabs $28M for latest tech to restore sight to the blind. News

> Scientists create digital 'magic wand' to improve at-home device cybersecurity. Story

> Voice box maker Atos Medical goes on the chopping block for €1 billion: WSJ. Article

Biotech News

@FierceBiotech: PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators' doors to ataluren. Article | Follow @FierceBiotech

@JohnCFierce: Does Roche's IL-13 setback in PhIII signal similar trouble ahead for AstraZeneca? Story | Follow @JohnCFierce

@DamianFierce: Hillary Clinton: enemy of Gut Guy. Watch | Follow @DamianFierce

> Savara raises $20M to push its inhaled antibiotic into Phase III. News

> ProMetic raises $30 million. Item

> Ipsen bets up to $855M on Exelixis' once-failed cancer drug. Article

Pharma Manufacturing News

> Lupin plans to add plant in Japan. News

> Potentially tainted heparin from China uncovered by French regulators. Report

> CMO helps TxCell move forward with clinical supplies after pilot plant closed. Item

> Novartis' Alcon unit recalls eye drop vials over questionable sterility. Story

> New plant to be online in UAE by end of 2016. Article

Pharma Asia News

> Bayer incoming CEO highlights OTC challenges in China in three-way integration. More

> China FDA prioritizes innovative drugs as 2015 approvals dipped. Story

> China's Mindray gets shareholder nod for reduced management-led buyout. Report

> China FDA chief Bi updates press on quality crackdown. More

> South Korea approved more clinical trials in 2015. Article

Drug Delivery News

> Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections. Item

> Sweden's Redwood gets private placement for its sustained-release dry eye disease candidate. Story

> AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics. Article

> J&J, ViiV tout trial showing their long-acting HIV-fighting injectables are comparable to daily pills. More

> U.K.-Netherlands startups join forces for robot-assisted gene delivery to the eye. Article

And Finally... Monsanto is benefitting from an addition to a chemical safety bill that could help shield it from legal liability for a toxic chemical. Report (sub. req.)